Document Detail


Interleukin-6 gene polymorphisms and susceptibility to myocardial infarction: the ECTIM study. Etude Cas-Témoin de l'Infarctus du Myocarde.
MedLine Citation:
PMID:  11485024     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
There is growing evidence that interleukin (IL) 6 plays an important role in the atherosclerotic process because of its role in mediating immune and inflammatory responses and inducing cell proliferation. The present study examined whether molecular variations at the IL-6 locus are involved in the predisposition to myocardial infarction. The entire coding region, 1,158 bp of the 5' flanking region and 237 bp of the 3' flanking region of the IL-6 gene were screened. We detected three nucleotide substitutions in the 5' region at positions -174 (G/C), -572 (G/C), and -596 (G/A) from the transcription start site, and one insertion/deletion in the 3' region at position +528 after the Stop codon. These polymorphisms were genotyped in the Etude Cas-Témoin de l'Infarctus du Myocarde study comparing male patients (n=640) and age-matched controls (n=719) from Northern Ireland and France. The IL-6/G-174C and IL-6/G-596A polymorphisms were in nearly complete association. Carriers of the IL-6/-174 C allele were more frequent in patients than in controls. The population-adjusted odds ratio for myocardial infarction associated with genotype CC+CG vs. GG was estimated as 1.34. In French patients the number of coronary arteries with greater than 50% stenosis was assessed by angiography. The IL-6/-174 C allele was more frequent in patients with two or fewer stenosed vessels than in patients with three-vessel lesions. These results suggest that genetic variation at the IL-6 locus is associated with susceptibility to myocardial infarction, especially events occurring on less extended lesions. These findings would be compatible with a lower IL-6 secretion associated with the IL-6/-174 C allele, itself or in combination with other promoter polymorphisms, leading to more unstable plaques.
Authors:
J L Georges; V Loukaci; O Poirier; A Evans; G Luc; D Arveiler; J B Ruidavets; F Cambien; L Tiret
Related Documents :
21920304 - Revitalizing our view of heart development.
18525354 - Psoriasis and metabolic disease: epidemiology and pathophysiology.
8776784 - Is obstructive sleep apnea (osa) a risk factor for myocardial infarction and cardiac ar...
25160814 - Left ventricular shape variation in asymptomatic populations: the multi-ethnic study of...
12602484 - Assessment of myocardial viability in a porcine model of chronic coronary artery stenos...
17046854 - Early complications of stenting in patients with congenital heart disease: a multicentr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Journal of molecular medicine (Berlin, Germany)     Volume:  79     ISSN:  0946-2716     ISO Abbreviation:  J. Mol. Med.     Publication Date:  2001 Jun 
Date Detail:
Created Date:  2001-08-03     Completed Date:  2002-01-25     Revised Date:  2011-07-08    
Medline Journal Info:
Nlm Unique ID:  9504370     Medline TA:  J Mol Med (Berl)     Country:  Germany    
Other Details:
Languages:  eng     Pagination:  300-5     Citation Subset:  IM    
Affiliation:
INSERM U525, Faculté de Médecine, Paris, France.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Case-Control Studies
France
Gene Frequency
Genetic Predisposition to Disease / genetics*
Humans
Interleukin-6 / genetics*
Male
Middle Aged
Multicenter Studies as Topic
Myocardial Infarction / genetics*
Northern Ireland
Polymerase Chain Reaction
Polymorphism, Genetic / genetics*
Polymorphism, Single-Stranded Conformational
Promoter Regions, Genetic / genetics
Smoking
Chemical
Reg. No./Substance:
0/Interleukin-6

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Polymorphisms in human apolipoprotein(a) kringle IV-10 and coronary artery disease: relationship to ...
Next Document:  Shock waves: a novel method for cytoplasmic delivery of antisense oligonucleotides.